title: Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors.
abstract: We compared two doses of recombinant human granulocyte-stimulating factor (G-CSF) for stem cell mobilisation in 90 healthy donors for allogeneic stem cell transplantation in a retrospective analysis. Group I (n = 46) received 10 microg/kg G-CSF (filgrastim) given as 5 microg/kg twice daily, and group II (n = 44) received 16 microg/kg, given as 8 microg/kg twice daily with a 12-h interval. The groups were well-balanced for age and body-weight. G-CSF application was performed on an out-patient basis, and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were grade I/II, bone pain, headache and fatigue in both groups, whereas grade III of bone pain, headache and fatigue occurred in the 2 x 8 microg/kg group only. One serious non-fatal event with non-traumatic spleen rupture occurred in the 2 x 5 microg/kg group. The CD34(+)cell count in the first apheresis of all donors was 5.1 x 10(6)/kg donor weight (range, 1.5-19.3). The CD34(+) cell harvest was higher in the 2 x 8 microg/kg group than in the 2 x 5 microg/kg group (7.1 x 10(6)/kg vs 4.9 x 10(6)/kg; P = 0.09). The target of collecting >5.0 x 10(6) CD34(+) cells/kg donor weight with one apheresis procedure was achieved in 45% of group I and in 61% of group II, respectively. Administering G-CSF at a dosage of 8 microg/kg twice daily leads to a higher CD34(+) cell yield than a dosage of 2 x 5 microg/kg, but is associated with increased toxicity and higher cost.
authors.affiliation: Department of Bone Marrow Transplantation, University of Hamburg, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: H
authors.initials: H
authors.lastname: Renges
authors.forename: S
authors.initials: S
authors.lastname: Sonnenberg
authors.forename: W
authors.initials: W
authors.lastname: Krüger
authors.forename: K
authors.initials: K
authors.lastname: Gutensohn
authors.forename: T
authors.initials: T
authors.lastname: Dielschneider
authors.forename: L
authors.initials: L
authors.lastname: Cortes-Dericks
authors.forename: A R
authors.initials: AR
authors.lastname: Zander
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D001781:Blood Component Removal; D001782:Blood Donors; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000633:toxicity; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods* / Q000592:standards; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000379:methods
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor